Intraocular Inflammation More Common With Aflibercept Injections in Real-World Setting
By Lori Solomon HealthDay Reporter
FRIDAY, May 9, 2025 -- The incidence of mild intraocular inflammation (IOI) in the real world occurs more frequently after intravitreal injection of aflibercept than in clinical trials, according to a study published online May 1 in JAMA Ophthalmology.
Karoline E. Binder, M.D., from the Technical University of Munich, and colleagues assessed the incidence of IOI after intravitreal injection of aflibercept, 8 mg, in real-world practice. The analysis included 41 patients (23 with neovascular age-related macular degeneration and 18 with diabetic macular edema) who were treated with 136 intravitreal aflibercept, 8 mg, injections.
The researchers reported that five patients developed mild sterile IOI within one to three days after the intervention (incidence per injection, 3.7 percent; incidence per patient, 12 percent). Only one patient developed inflammation after the first dose, while the other four had prior exposure to aflibercept. All patients were treated with local anti-inflammatory therapy (topical or subconjunctival corticosteroids), while two patients received additional systemic oral corticosteroids. After IOI resolved, there was no reduction in best-corrected visual acuity.
"Although the IOI found in this series can be considered mild, careful evaluation of patient-associated risk factors and thorough patient education are warranted," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-05-10 06:00
Read more

- FDA Announces Expanded Use of Unannounced Inspections at Foreign Manufacturing Facilities
- Eviction Bans Linked To Drop In Child Abuse Reports
- Metabolic Syndrome Linked to Increased Risk for Young-Onset Dementia
- Targeted Grant Terminations Have Affected 694 NIH Grants
- Showerhead Water Limits Rescinded as Trump Targets Household Appliances
- Uplizna (inebilizumab-cdon) is Now the First and Only FDA-Approved Treatment for IgG4-Related Disease
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions